Siu-Lung Chan

Siu-Lung (Kelvin) Chan is a highly experienced Senior Scientist at Enanta Pharmaceuticals, where significant contributions include investigating the pharmacokinetic profiles of EDP-235, leading to a successful Phase II clinical trial for a COVID-19 antiviral, and conducting in vivo studies on EDP-323 for respiratory syncytial virus treatment. Additionally, Kelvin Chan serves as a Scientific Writing Consultant for Accdon, LLC and Creaducate Consulting GmbH, focusing on editing and translating biomedical manuscripts. Previous roles include Staff Scientist at Harvard Medical School, where collaborations with Innolign Biomedical highlighted the effects of a ROCK2 inhibitor on lymphedema, and several positions at the University of Vermont and The University of Iowa, involving critical research on stroke outcomes and hypertension. Kelvin Chan holds a PhD in Pharmacology from The Chinese University of Hong Kong and is currently pursuing a Graduate Certificate in Biotechnology Management at Harvard Extension School.